Drugs / Botulism Antitoxin Heptavalent (Equine) Types A-G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00636519 | Feb 2008 → Oct 2009 | — | Emergent BioSolutions | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Botulism Antitoxin Heptavalent (Equine) Types A-G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00636519 ↗ |
| Known as | NP-018 | “NP-018 (heptavalent equine-derived botulinum antitoxin)” NCT00636519 ↗ |
| Action | Inhibit | “To assess the ability of botulism antitoxin (heptavalent, Cangene) to neutralize Botulinum toxin in the Extensor Digitorum Brevis model of muscle paralysis in Stage B.” NCT00636519 ↗ |
| Modality | Protein / enzyme biologic | “NP-018 (heptavalent equine-derived botulinum antitoxin) is prepared from plasma obtained from horses that have been immunized with a specific subtype of botulinum toxoid and toxin.” NCT00636519 ↗ |